386 related articles for article (PubMed ID: 29905933)
1. The classification of pediatric and young adult renal cell carcinomas registered on the children's oncology group (COG) protocol AREN03B2 after focused genetic testing.
Cajaiba MM; Dyer LM; Geller JI; Jennings LJ; George D; Kirschmann D; Rohan SM; Cost NG; Khanna G; Mullen EA; Dome JS; Fernandez CV; Perlman EJ
Cancer; 2018 Aug; 124(16):3381-3389. PubMed ID: 29905933
[TBL] [Abstract][Full Text] [Related]
2. Translocation carcinomas of the kidney.
Argani P
Genes Chromosomes Cancer; 2022 May; 61(5):219-227. PubMed ID: 34704642
[TBL] [Abstract][Full Text] [Related]
3. [Clinicopathologic and molecular genetic study of renal cell carcinoma occurring in teenagers].
Rao Q; Zhou J; Zhang RS; Ma HH; Zhou HB; Lu ZF; Zhou XJ
Zhonghua Bing Li Xue Za Zhi; 2010 Sep; 39(9):582-6. PubMed ID: 21092583
[TBL] [Abstract][Full Text] [Related]
4. Characteristics and outcome of pediatric renal cell carcinoma patients registered in the International Society of Pediatric Oncology (SIOP) 93-01, 2001 and UK-IMPORT database: A report of the SIOP-Renal Tumor Study Group.
van der Beek JN; Hol JA; Coulomb-l'Hermine A; Graf N; van Tinteren H; Pritchard-Jones K; Houwing ME; de Krijger RR; Vujanic GM; Dzhuma K; Schenk JP; Littooij AS; Ramírez-Villar GL; Murphy D; Ray S; Al-Saadi R; Gessler M; Godzinski J; Ruebe C; Collini P; Verschuur AC; Frisk T; Vokuhl C; Hulsbergen-van de Kaa CA; de Camargo B; Sandstedt B; Selle B; Tytgat GAM; van den Heuvel-Eibrink MM
Int J Cancer; 2021 Jun; 148(11):2724-2735. PubMed ID: 33460450
[TBL] [Abstract][Full Text] [Related]
5. Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service.
Green WM; Yonescu R; Morsberger L; Morris K; Netto GJ; Epstein JI; Illei PB; Allaf M; Ladanyi M; Griffin CA; Argani P
Am J Surg Pathol; 2013 Aug; 37(8):1150-63. PubMed ID: 23715164
[TBL] [Abstract][Full Text] [Related]
6. TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum.
Rao Q; Williamson SR; Zhang S; Eble JN; Grignon DJ; Wang M; Zhou XJ; Huang W; Tan PH; Maclennan GT; Cheng L
Am J Surg Pathol; 2013 Jun; 37(6):804-15. PubMed ID: 23598965
[TBL] [Abstract][Full Text] [Related]
7. MiT family translocation renal cell carcinoma.
Argani P
Semin Diagn Pathol; 2015 Mar; 32(2):103-13. PubMed ID: 25758327
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic utility of one-stop fusion gene panel to detect TFE3/TFEB gene rearrangement and amplification in renal cell carcinomas.
Harada S; Caliò A; Janowski KM; Morlote D; Rodriguez Pena MD; Canete-Portillo S; Harbi D; DeFrank G; Magi-Galluzzi C; Netto GJ; Martignoni G; Mackinnon AC
Mod Pathol; 2021 Nov; 34(11):2055-2063. PubMed ID: 34148064
[TBL] [Abstract][Full Text] [Related]
9. Proximal CD13 Versus Distal GATA-3 Expression in Renal Neoplasia According to WHO 2016 Classification.
Brunelli M; Erdini F; Cima L; Eccher A; Fioravanzo A; Gobbo S; Segala D; Ghimenton C; Mazzoleni G; Munari E; Carella R; Martignoni G
Appl Immunohistochem Mol Morphol; 2018; 26(5):316-323. PubMed ID: 27556823
[TBL] [Abstract][Full Text] [Related]
10. Histological and molecular characterization of TFEB-rearranged renal cell carcinomas.
Wyvekens N; Rechsteiner M; Fritz C; Wagner U; Tchinda J; Wenzel C; Kuithan F; Horn LC; Moch H
Virchows Arch; 2019 May; 474(5):625-631. PubMed ID: 30706129
[TBL] [Abstract][Full Text] [Related]
11. Translocation renal cell carcinoma: lack of negative impact due to lymph node spread.
Geller JI; Argani P; Adeniran A; Hampton E; De Marzo A; Hicks J; Collins MH
Cancer; 2008 Apr; 112(7):1607-16. PubMed ID: 18278810
[TBL] [Abstract][Full Text] [Related]
12. SFPQ/PSF-TFE3 renal cell carcinoma: a clinicopathologic study emphasizing extended morphology and reviewing the differences between SFPQ-TFE3 RCC and the corresponding mesenchymal neoplasm despite an identical gene fusion.
Wang XT; Xia QY; Ni H; Ye SB; Li R; Wang X; Shi SS; Zhou XJ; Rao Q
Hum Pathol; 2017 May; 63():190-200. PubMed ID: 28315422
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic and Molecular Analysis of the TFEB Fusion Variant Reveals New Members of TFEB Translocation Renal Cell Carcinomas (RCCs): Expanding the Genomic Spectrum.
Xia QY; Wang XT; Fang R; Wang Z; Zhao M; Chen H; Chen N; Teng XD; Wang X; Wei X; Ye SB; Li R; Ma HH; Lu ZF; Zhou XJ; Rao Q
Am J Surg Pathol; 2020 Apr; 44(4):477-489. PubMed ID: 31764220
[TBL] [Abstract][Full Text] [Related]
14. TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.
Argani P; Zhong M; Reuter VE; Fallon JT; Epstein JI; Netto GJ; Antonescu CR
Am J Surg Pathol; 2016 Jun; 40(6):723-37. PubMed ID: 26975036
[TBL] [Abstract][Full Text] [Related]
15. [The translocation carcinoma: A pediatric renal tumor also in adults].
Bruder E; Moch H
Pathologe; 2016 Mar; 37(2):159-65. PubMed ID: 26972595
[TBL] [Abstract][Full Text] [Related]
16. Renal cell carcinomas with t(6;11)(p21;q12): A clinicopathologic study emphasizing unusual morphology, novel alpha-TFEB gene fusion point, immunobiomarkers, and ultrastructural features, as well as detection of the gene fusion by fluorescence in situ hybridization.
Rao Q; Liu B; Cheng L; Zhu Y; Shi QL; Wu B; Jiang SJ; Wang Y; Wang X; Yu B; Zhang RS; Ma HH; Lu ZF; Tu P; Wang JD; Zhou XJ
Am J Surg Pathol; 2012 Sep; 36(9):1327-38. PubMed ID: 22895266
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms underlying the MiT translocation subgroup of renal cell carcinomas.
Medendorp K; van Groningen JJ; Schepens M; Vreede L; Thijssen J; Schoenmakers EF; van den Hurk WH; Geurts van Kessel A; Kuiper RP
Cytogenet Genome Res; 2007; 118(2-4):157-65. PubMed ID: 18000366
[TBL] [Abstract][Full Text] [Related]
18. [MiT family translocation renal cell carcinomas: Natural history, molecular features and multidisciplinary management].
Herrscher H; Boilève A; Lindner V; Barthélémy P; Hutt É; Pierard L; Kurtz JE; Rioux-Leclercq N; Lang H; Malouf GG
Bull Cancer; 2020 Feb; 107(2):272-280. PubMed ID: 32044098
[TBL] [Abstract][Full Text] [Related]
19. TRIM63 is a sensitive and specific biomarker for MiT family aberration-associated renal cell carcinoma.
Wang XM; Zhang Y; Mannan R; Skala SL; Rangaswamy R; Chinnaiyan A; Su F; Cao X; Zelenka-Wang S; McMurry L; Xiao H; Spratt DE; Sangoi AR; Shao L; Betz BL; Brown N; Tickoo SK; McKenney JK; Argani P; Gupta S; Reuter VE; Chinnaiyan AM; Dhanasekaran SM; Mehra R
Mod Pathol; 2021 Aug; 34(8):1596-1607. PubMed ID: 33854184
[TBL] [Abstract][Full Text] [Related]
20. Renal cell carcinoma in children and adolescents: a retrospective study of a French-Italian series of 93 cases.
Denize T; Massa S; Valent A; Militti L; Bertolotti A; Barisella M; Rioux-Leclercq N; Malouf GG; Spreafico F; Verschuur A; van der Beek J; Tytgat L; van den Heuvel-Eibrink MM; Vujanic G; Collini P; Coulomb A
Histopathology; 2022 May; 80(6):928-945. PubMed ID: 35238063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]